Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The site footer now shows revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-02T16:11:49.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    A sitewide notice announces NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:36:53.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:16:54.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer’s revision number changes from v3.7.0 to v3.7.1; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-12T14:44:45.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study record with a generic error message and site navigation; the previous study-related content has been removed and only standard site boilerplate remains.
    Difference
    17%
    Check dated 2026-09-21T22:23:35.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Revision: v3.6.6 replaces the prior v3.6.5 on the page, indicating a minor update to the site’s revision stamp. No user-facing content changes are indicated.
    Difference
    0.0%
    Check dated 2026-08-31T17:14:22.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.